# EDGAR Filing Document

**Accession Number:** 0002022953
**File Stem:** 0000000000-25-006146
**Filing Date:** 2025-6
**Character Count:** 4605
**Document Hash:** ac611ac1d58994e50560afd74a29700b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006146.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0000000000-25-006146

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250611

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TheRas, Inc.
- **CENTRAL INDEX KEY:** 0002022953
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-07895

**BUSINESS ADDRESS:**
- **STREET 1:** 3160 PORTER DRIVE SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** 6504057021

**MAIL ADDRESS:**
- **STREET 1:** 3160 PORTER DRIVE SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Oncology Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001869105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-07895

**BUSINESS ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 857 702 0377

**MAIL ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp. II
- **DATE OF NAME CHANGE:** 20210623
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-031720

## Text-Extract

```

                                                            June 11, 2025

Bihua Chen
Chief Executive Officer
Helix Acquisition Corp. II
200 Clarendon Street, 52nd Floor
Boston, MA 02116

Eli Wallace
Chief Executive Officer
TheRas, Inc.
256 E. Grand Avenue, Suite 104
South San Francisco, CA 94080

       Re: Helix Acquisition Corp. II
           TheRas, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-4
           Submitted May 30, 2025
           CIK No. 0001869105
Dear Bihua Chen and Eli Wallace:

     We have reviewed your amended draft registration statement and have the
following
comments.

       Please respond to this letter by providing the requested information and
either
submitting an amended draft registration statement or publicly filing your
registration
statement on EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

      After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 1 to Draft Registration Statement on Form S-4
Dilution, page 236

1.     We note the revisions made to your tabular dilution disclosure in
response to prior
       comment 10. Please revise your calculation of net tangible book value
per share for
 June 11, 2025
Page 2

       each redemption scenario to exclude the effects of the Business
Combination. In this
       regard, we note that you currently include an adjustment to the
numerator to reflect
       BBOT net assets and an adjustment to the denominator to reflect
conversion of BBOT
       shares into PubCo common stock. Item 1604(c) of Regulation S-K specifies
that net
       tangible book value per share, as adjusted should exclude the de-SPAC
transaction
       itself.
Information about BBOT
BBOT's Business, page 260

2.     We note your response to prior comment 15. Please revise this section to
disclose
       when you expect to complete enrollment for each of your clinical trials,
so that
       investors can better understand your trial progress.
       Please contact Bonnie Baynes at 202-551-4924 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please contact Tyler Howes at 202-551-3370 or Joshua Gorsky at
202-551-7836
with any other questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Joel Rubinstein, Esq.
      Maggie L. Wong, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._